Abstract: The present invention provides polynucleotides derived from cDNA of novel type of hepatitis C virus named Korean type hepatitis C virus (KHCV), polypeptides encoded therein, and antibodies directed against the polypeptides; and also provide diagnostics and vaccines employing any of the above materials as active ingredient(s).

Abstract: The present invention relates to the epitopes of hepatitis C virus (HCV) core protein and non-structural 3 protein (NS3), and the epitopes of envelope protein, epitopes of non-structural 4 protein, and the epitopes of HCV non-structural 5 protein and a recombinant protein comprising the same; processes for producing the recombinant proteins; an agent for diagnosing antibodies against hepatitis C virus in a putative serum sample, which comprises said recombinant proteins; and a process for diagnosing hepatitis C by using the agent.

Abstract: Cis-epoxide compounds of formula (I-3) and pharmaceutically acceptable salts, hydrates and solvates thereof: ##STR1## wherein: R.sup.1 is a cycloalkyl, or arly-substituted lower alkyl group;K and J are independently a group having the formula of ##STR2## wherein R.sup.18 is a lower alkyl group optionally substituted with an aryl radical; X is O, NH, or N--CH.sub.3 ; and R.sup.19 is an aromatic hetercyclic sysstem containing a nitrogen atom in its ring, or a lower alkyl group optionally substituted with an aryl radical, or a hydrogen;G is an amino acid which is linked to K-- and ##STR3## by peptide bonds in formula (I-3); Q is an amino acid which is linked toby peptide bonds in formula (I-3), or a group having the formula ofwherein R.sup.20 is a lower alkyl group optionally substituted with an aromatic radical; and Y is CH.sub.2, O or NH; andr is 0 or 1, except that Q is a group having the formula ofr is 0.

Abstract: Cis-epoxide compounds of formula (I-1) and pharmaceutically acceptable salts, hydrates and solvates thereof: ##STR1## wherein: R.sup.1 is a cycloalkyl, or aryl-substituted lower alkyl group;A is a functionalized acyl group of the formula ##STR2## wherein R.sup.2 is a C.sub.1-4 alkyl, or amide-substituted C.sub.1-2 alkyl group;R.sup.3 is a C.sub.1-4 alkoxy, aryloxyalkyl or arylalkoxy, or a nitrogen-containing aromatic radical, or a lower alkoxy group substituted with a nitrogen-containing aromatic radical, or a radical having the formula of ##STR3## wherein R.sup.4 is a hydrogen or a methyl group and R.sup.5 is an alkyl group substituted with a nitrogen-containing aromatic radical; and m is 0 or 1; and B is a functionalized amino group of the formula ##STR4## wherein R.sup.8 and R.sup.9 are independently a C.sub.1-4 alkyl group optionally substituted with an aromatic radical, or an aromatic group.

Abstract: A spherical heat storage capsule having improved thermal properties includes a spherical core of a latent heat storage material having a diameter ranging from 0.1 to 10 mm, at least one layer of a hydrophobic wax and one to three layers of polymeric materials.

Abstract: A coating composition having excellent antifogging property, good abrasion resistance, improved adhesion to the substrate and good water resistance, which comprises an epoxy functional organosilane or the hydrolysate or condensate thereof; an amino functional organosilane or the hydrolysate or condensate thereof; a hydrophilic (meth)acrylate monomer, or a copolymer of two components selected from the hydrophilic (meth)acrylate monomer, another hydrophilic monomer and an organosilane and/or a terpolymer of the three components; a curing catalyst; and, optionally, a multi-functional (meth)acrylate monomer having at least two (meth)acryl groups and a radical polymerization initiator.

Abstract: A coating composition having excellent antifogging property, good abrasion resistance, improved adhesion to the substrate and good water resistance, which comprises an epoxy functional organosilane or the hydrolysate or condensate thereof; an amino functional organosilane or the hydrolysate or condensate thereof; a hydrophilic (meth)acrylate monomer, or a copolymer of two components selected from the hydrophilic (meth)acrylate monomer, another hydrophilic monomer and an organosilane and/or a terpolymer of the three components; a curing catalyst; and, optionally, a multi-functional (meth)acrylate monomer having at least two (meth)acryl groups and a radical polymerization initiator.

Abstract: The present invention relates to a release-controlled implantable composition comprising somatotropin, a bio-compatible wax and a water-soluble polymer. The present composition exhibits superior sustained effect with little side effects, which renders it suitable for long-term administration.

Abstract: Polymeric glass modifier having a partially crosslinked structure capable of effectively reducing the surface gloss of a thermoplastic resin, is prepared by (a) emulsion polymerizing an acrylic monomer, an ethylenically unsaturated cyanide compound end, optionally, an aromatic vinyl monomer to obtain a copolymer latex of a linear structure; (b) conducting a crosslinking emulsion polymerization of the resultant linear copolymer latex obtained in step (a) with an addition of the same monomers used in step (a), an acrylamide inter-particle crosslinking agent and an ethylenically unsaturated crosslinking agent to produce a partially crosslinked latex; and (c) coagulating and interparticle crosslinking the partially crosslinked latex obtained in step (b) with an addition of an acid to obtain the polymeric gloss modifier.

Abstract: The present invention provides cis-epoxide compounds represented by formula (I-1), (I-2) or (I-3) which are useful for treating or preventing diseases caused by HIV infection: ##STR1## wherein: A, B, D, E, R.sup.1, R.sup.10, R.sup.11, K, G, Q, r and J have the meanings as defined in the specification.

Abstract: Polymeric gloss modifiers, are prepared by forming polymer latices of a core/shell structure or a multi-layered structure, and coagulating and interparticle crosslinking the polymer latices. Said modifiers are used in preparing a low gloss thermoplastic resin compound.

Abstract: Cephalosporin compounds of formula (I): ##STR1## wherein: R.sup.1 is a hydrogen or an amino protecting group;R.sup.2 and R.sup.3 are, independently, a hydrogen or a hydroxy protecting group, or form together a cyclic diol protecting group;R.sup.4 and R.sup.5 are, independently, a hydrogen or a carboxyl protecting group;X and Y are a nitrogen and a carbon atom, respectively, or a carbon and a nitrogen atom, respectively;R.sup.6 and R.sup.7 are, independently, a hydrogen or an amino, substituted amino, hydroxy, alkoxy, C.sub.1-4 alkyl, carboxyl or alkoxy carbonyl group, or jointly form a C.sub.3-7 cycloalkyl group together with the carbon to which they are attached, when X and Y are a nitrogen and a carbon, respectively, or R.sup.7 is a hydrogen or an amino group when X and Y are a carbon and a nitrogen, respectively; andQ is .dbd.CH-- or .dbd.

Abstract: An extracellular leucine aminopeptidase was isolated from the culture medium of Streptomyces therrnonitrificans which is a Zn.sup.2+ -dependent metalloenzyme which comprises an amino acid sequence Lys-Phe-Ser-Lys-Lys-Phe-Asn-Glu (SEQ ID NO: 3) at the N-terminal thereof, and amino acid sequences of Glu-Pro-Gly-Thr-Gly-Ala-Leu-Glu-Pro (SEQ ID NO: 4) and Asn-Pro-Asp-Ile-Val-Tyr (SEQ ID NO: 5) at other regions thereof. The aminopeptidase has a pH optimum of 7.5 to 9.0, a temperature optimum of 30.degree. to 50.degree. C., and an apparent molecular weight as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions of 41 to 45 kDa, and as determined by gel filtration under native state conditions of 36 to 40 kDa.

Abstract: The present invention relates to a novel process for preparing sulfonylurea derivatives of formula (I) in a high purity and a high yield characterized in that a sulfonylchloride of formula (V) is reacted with 2-amino-4,6-dimethoxypyrimidine of formula (VII) in the presence of a metal cyanate and an organic base catalyst or a compound of formula (VIII) is reacted with 2-amino-4,6-dimethoxypyrimidine of formula (VII): ##STR1## wherein R.sup.1 represents hydrogen, C.sub.1 -C.sub.4 alkyl or phenyl, R.sup.2 represents hydrogen, C.sub.1 -C.sub.4 alkyl, allyl or propargyl and R.sup.3 represents hydrogen, methyl, ethyl or phenyl, and to a process for preparing the sulfonylchloride compound of formula (V) above and the compound of formula (VIII) above, both of which are useful as an intermediate compound for preparing the sulfonylurea derivative of formula (I) and to a novel intermediate compound of formula (VIII) as defined above.

Abstract: The present invention provides an improved process for preparing a highly water absorbent resin having a superior suction power and excellent gel strength, which consists essentially of:(1) neutralizing acrylic acid to a neutralization degree ranging from 50 to 100% based on the total number of moles of the acid employed and polymerizing it by a reverse phase suspension polymerization to provide a neutralized polymer;(2) dehydrating the polymer until its water content reaches 25% by weight or less based on the weight of the polymer through an azeotropic distillation thereof in the presence of a lipophilic solvent;(3) crosslinking the dehydrated polymer in the presence of a hydrophilic crosslinking agent containing at least two epoxy groups in an amount ranging from 0.05 to 5.0% by weight and water added in an amount ranging from 7.0 to 25.

Abstract: The present invention relates to a strain of Streptococcus zooepidemicus which produces high molecular weight hyaluronic acid; to a process for preparing said hyaluronic acid by employing the strain; and to a medium suitable for the culture of a microorganism producing hyaluronic acid.

Abstract: The present invention provides a cephalosporin compound represented by formulas (I-S) and (I-R) ##STR1## wherein: R.sup.1 is a C.sub.1-4 alkyl, C.sub.3-4 alkenyl, C.sub.3-4 cycloalkyl, amino optionally substituted with a C.sub.1-4 alkyl radical, phenyl, or 2-,4- or 6- substituted phenyl group with two or fewer substitutents chosen from C.sub.1-4 alkyl, C.sub.1-3 alkoxy, halogen and hydroxy radicals;R.sup.2 is hydrogen or a C.sub.1-4 alkyl group;R.sup.a and R.sup.b, which should be different from each other, are hydrogen or a C.sub.1-4 alkyl group; andQ is N or CH,and the pharmaceutically acceptable non-toxic salts, physiologically hydrolyzable esters, hydrates and solvates thereof, which possess potent and broad antibacterial activities. The invention also provides processes for preparing these compounds and to pharmaceutical compositions containing them as active ingredients.

Abstract: The present invention relates to a process for preparing a partially crosslinked binder resin useful for electrophotographic toner, which comprises:(1) preparing a partially crosslinked polymer by way of: a non-crosslinking emulsion polymerization of an aromatic vinyl monomer, an acrylic monomer and a cyanide compound in a linear structure, and a cross-linking polymerization of an aromatic vinyl monomer, an acrylic monomer, a cyanide compound and an unsaturated carboxylic acid or an unsaturated monomer containing an epoxy group; and(2) coagulating the polymer latex obtained in step(1) in the presence of a water soluble amine.

Abstract: The present invention relates to novel cephalosporin compounds, pharmaceutically acceptable non-toxic salts, physiologically hydrolyzable esters, hydrates and solvates and isomers thereof which possess potent and broad antibacterial activities. The compounds of the present invention have a (4-amino-1-substituted-alkapyrimidinium-4-yl)thiomethyl group in 3-position of the cephem nucleus and is specifically represented by the following formula(I): ##STR1## wherein: R.sup.1 is a hydrogen atom or a C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl or --C(R.sup.A)(R.sup.B)COOH group wherein R.sup.A and R.sup.B are independently a hydrogen atom or a C.sub.1-4 alkyl group, or form a C.sub.3-7 cycloalkyl group together with the carbon atom to which they are attached;R.sup.2 is an unsubstituted or substituted amino, C.sub.1-4 alkyl or C.sub.3-7 cycloalkyl group; andn is an integer ranging from 2 to 7.

Abstract: The present invention relates to a process for the selective preparation of 4,4-methylene-bis-(N-phenylalkylcarbamate) which comprises condensing N-phenylalkylcarbamate with a methylating agent in the presence of an acidic ion-exchange resin or an aqueous acid as a catalyst and a non polar aprotic solvent and filtrating a condensation product at a temperature greater than the melting point of N-phenylalkylcarbamate to separate 4,4-methylene-bis-(N-phenylalkylcarbamate).